Mount Yale Investment Advisors LLC Has $214,000 Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Mount Yale Investment Advisors LLC trimmed its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 8.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,879 shares of the company’s stock after selling 172 shares during the period. Mount Yale Investment Advisors LLC’s holdings in BioNTech were worth $214,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Fred Alger Management LLC acquired a new position in shares of BioNTech in the 3rd quarter valued at about $59,485,000. Baillie Gifford & Co. increased its stake in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after buying an additional 7,340 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of BioNTech by 412.3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after acquiring an additional 33,375 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Down 2.5 %

BNTX opened at $121.16 on Thursday. The business has a 50 day moving average of $116.88 and a 200-day moving average of $106.67. The stock has a market capitalization of $29.05 billion, a price-to-earnings ratio of -57.69 and a beta of 0.18. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period in the prior year, the firm earned $0.73 EPS. The business’s revenue was up 38.9% on a year-over-year basis. As a group, sell-side analysts anticipate that BioNTech SE will post -3.77 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BNTX. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. Berenberg Bank initiated coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. HSBC increased their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, Wells Fargo & Company assumed coverage on shares of BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.